Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | PLK1 | P53350 | 4/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 4/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557833 | 0.89 | PLK1 (0.37) | IGF1RPLK1CDK2VNN1RPS6KB1 | |
| SCHEMBL3552605 | 0.89 | PLK1 (0.36) | IGF1RPLK1CDK2MAPK14RPS6KB1 | |
| SCHEMBL3546245 | 0.89 | IKBKB (0.35) | MAPK1IGF1RPLK1CDK2MAPK14 | |
| SCHEMBL3551908 | 0.88 | PLK1 (0.36) | MAPK1IGF1RPLK1CDK2MAPK14 | |
| SCHEMBL3551209 | 0.84 | GUCY1B2 (0.38) | IGF1RPLK1CDK2VNN1RPS6KB1 | |
| SCHEMBL3557835 | 0.84 | PLK1 (0.37) | IGF1RPLK1CDK2VNN1RPS6KB1 | |
| SCHEMBL3556289 | 0.84 | PLK1 (0.39) | IGF1RPLK1CDK2MAPK14RPS6KB1 | |
| SCHEMBL3549519 | 0.83 | PLK1 (0.34) | IGF1RPLK1CDK2VNN1 | |
| SCHEMBL3555390 | 0.83 | PLK1 (0.38) | IGF1RPLK1CDK2VNN1IDH1 | |
| SCHEMBL27691888 | 0.82 | PLK1 (0.34) | PLK1MAPK14RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | MAPK1 390/4885IGF1R 101/4885PLK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.